Journal article
Selective targeting BMP2 and 4 in SMAD4 negative esophageal adenocarcinoma inhibits tumor growth and aggressiveness in preclinical models
S Li, SJM Hoefnagel, M Read, S Meijer, MI van Berge Henegouwen, SS Gisbertz, E Bonora, DSH Liu, WA Phillips, S Calpe, ACP Correia, MDC Sancho-Serra, S Mattioli, KK Krishnadath
Cellular Oncology | SPRINGER | Published : 2022
Open access
Abstract
Purpose: Abnormalities within the Sonic Hedgehog (SHH), Bone Morphogenetic Protein (BMP) and SMAD4 signalling pathways have been associated with the malignant behavior of esophageal adenocarcinoma (EAC). We recently developed two specific llama-derived antibodies (VHHs), C4C4 and C8C8, which target BMP4 and BMP2/4, respectively. Here we aimed to demonstrate the feasibility of the VHHs for the treatment of EAC and to elucidate its underlying mechanism. Methods: Gene Set Enrichment Analysis (GSEA) was performed on a TCGA dataset, while expression of SHH, BMP2/4 and SMAD4 was validated in a cohort of EAC patients. The effects of the VHHs were tested on the recently established SMAD4(-) ISO76A p..
View full abstractGrants
Awarded by European Research Council
Funding Acknowledgements
European Research Council (ERC-StG 282079; ERC-POC 632258), Dutch government grant (LSH-TKI-PPP 2017) and China Scholarship Council (201806170097)